Emrich H M, Zaudig M, Kissling W, Dirlich G, von Zerssen D, Herz A
Pharmakopsychiatr Neuropsychopharmakol. 1980 Sep;13(5):290-8. doi: 10.1055/s-2007-1019647.
A double-blind placebo-controlled cross-over investigation of the possible antipsychotic action of [des-Tyr1]-gamma-endorphin (DT gamma E) was undertaken in schizophrenic patients. This non-opiod derivative of gamma-endorphin has recently been shown to exert both neuroleptic-like effects in animals and an antipsychotic action in schizophrenic patients failing to respond to conventional neuroleptic therapy. 13 patients undergoing continuous neuroleptic therapy, and suffering from either chronic or acute, frequently-relapsing schizophrenia and displaying persistent productive symptoms (hallucinations, acute delusions) were selected for the trial. After one day of single-blind injection of placebo, two successive double-blind treatment periods of 4 days each followed, viz 4 days with i.m. injections of 2 mg DT gamma E preceding 4 days of placebo injections or vice versa. Psychopathological evaluation was performed twice daily by use of the IMPS and an eight-point-scale appropriate for the estimation of special target symptoms (VBS). The mean data obtained from the whole sample of 13 patients show that placebo and DT gamma E produce a reduction in symptomatology of an appoximately equal magnitude. The results provide no support for the hypothesis of an antipsychotic efficacy of DT gamma E in the treatment of chronic schizophrenic patients. In the subgroup of acute cases, however, a therapeutic action of DT gamma E appears possible
对[去酪氨酸1]-γ-内啡肽（DTγE）可能的抗精神病作用进行了一项双盲安慰剂对照交叉研究，研究对象为精神分裂症患者。γ-内啡肽的这种非阿片类衍生物最近已被证明在动物身上具有类似抗精神病药物的作用，并且对常规抗精神病药物治疗无效的精神分裂症患者具有抗精神病作用。选择了13名正在接受持续抗精神病药物治疗、患有慢性或急性、频繁复发的精神分裂症且表现出持续性阳性症状（幻觉、急性妄想）的患者进行试验。在单盲注射安慰剂一天后，接着是两个连续的双盲治疗期，每个治疗期为4天，即先进行4天肌肉注射2mg DTγE，随后4天注射安慰剂，或者反之。每天使用IMPS和一个适用于评估特殊目标症状（VBS）的八点量表进行两次精神病理学评估。从13名患者的整个样本中获得的平均数据表明，安慰剂和DTγE使症状学减轻的程度大致相等。结果不支持DTγE在治疗慢性精神分裂症患者方面具有抗精神病疗效的假设。然而，在急性病例亚组中，DTγE似乎可能具有治疗作用。
